Coronary Calcium Score for Men Over 40: The $100 Scan That Reclassifies Your Heart Risk

In 2008 the Multi-Ethnic Study of Atherosclerosis published coronary calcium data on 6,722 adults with no history of heart disease and reported that a score above 300 carried roughly ten times the risk of a coronary event compared with a score of zero, independent of every conventional risk factor. The scan that produced those scores is a non-contrast CT of the chest that takes about ten minutes and costs less than a pair of running shoes. This article covers what a coronary calcium score measures and what it misses, what the numbers look like for a man at 40, 50 and 60, why a zero is one of the most reassuring results in preventive medicine, how the score changes a statin decision, what testosterone therapy has to do with it, and what a man should actually do the week after his report comes back with a number on it.

A coronary artery calcium score is a number produced from a CT scan of the heart that quantifies how much calcified plaque sits in the walls of the coronary arteries. The scan uses no contrast dye, no needle and no treadmill, takes roughly ten minutes from changing room to car park, and exposes a man to about 1 millisievert of radiation, which is close to what a mammogram delivers and less than a year of natural background exposure. The output is a single figure called the Agatston score, named after the cardiologist Arthur Agatston who standardised the method in 1990.

The reason a calcium score matters more than a cholesterol panel for many men over 40 is that cholesterol is an input and calcium is an output. LDL cholesterol, ApoB, blood pressure and glucose describe the conditions under which coronary plaque might form. Calcified plaque on a CT is direct evidence that the process has been running, for years, inside the arteries of the specific man on the table. Two men with identical LDL of 145 mg/dL can have calcium scores of 0 and 400, and their ten year risk differs by an order of magnitude despite their bloodwork being interchangeable.

A coronary calcium score measures the total area and density of calcium deposits inside the walls of the coronary arteries, and it reports that burden as a single Agatston number that typically ranges from 0 to well over 1,000. The CT scanner identifies any lesion in the coronary arteries above 130 Hounsfield units of density, multiplies each lesion's area by a density weighting factor, and sums the results across the left main, left anterior descending, circumflex and right coronary arteries.

What the score does not measure is soft plaque. Atherosclerosis begins as lipid rich, non-calcified plaque that a non-contrast CT cannot see, and calcification is a later, healing phase of that process. A man's calcium score therefore lags the true extent of his disease by years, which is why a score of zero at age 42 is reassuring but not a guarantee, and why a heavy smoker with diabetes and a zero score is a different case from a lean non-smoker with the same zero. A CT coronary angiogram with contrast can visualise soft plaque directly, at higher cost and radiation, and is the right test when the calcium score and the clinical picture disagree.

The only truly normal calcium score is zero, and roughly 60 percent of men aged 40 to 49 in the MESA cohort had one. By age 50 to 59 that proportion fell to about 45 percent, and by 60 to 69 fewer than a third of men scored zero. Any non-zero score means calcified coronary plaque is present, and the clinical question shifts from whether a man has atherosclerosis to how much of it he has relative to other men his age.

Age percentile matters as much as the absolute number. A score of 50 in a 68 year old man sits below the median for his age and represents relatively slow disease progression. The same score of 50 in a 43 year old man places him above the 90th percentile for his age group and signals that plaque formation began early and is running ahead of schedule. The MESA calculator, freely available online, converts any score into an age, sex and ethnicity specific percentile, and that percentile is often the number a cardiologist reacts to more than the raw Agatston figure.

The bar chart illustrates the direction of the age trend rather than reproducing a single published table. The practical point is that a zero at 45 is unremarkable and expected, while a zero at 65 is a genuinely favourable finding that identifies a man whose arteries have resisted two extra decades of exposure. The corollary is that a non-zero score at 45 is a stronger signal than the same number at 65, because it arrived early.

A calcium score of zero is reassuring because it carries a ten year coronary event rate of roughly 1 to 2 percent in men over 40, which is low enough that a statin would need to be taken by more than 100 men for a decade to prevent a single event. In the MESA cohort, participants with a zero score and multiple risk factors had lower event rates than participants with no risk factors but a score above 100. The imaging result outperformed the risk factor count.

The concept researchers use is the warranty period. A 2010 analysis by Min and colleagues followed 4,864 adults with an initial score of zero and found that the conversion rate to a positive score was low enough that the average man could wait about four years before the probability of developing detectable calcium exceeded 25 percent. For men with diabetes or a strong family history, the warranty period shortens to roughly three years. That interval sets the sensible repeat frequency, and it also explains why a single zero at 42 does not settle the question forever.

The line chart is an approximation drawn from MESA and the CAC Consortium rather than a single published curve, and the exact figures differ by age, ethnicity and the definition of an event. The shape is consistent across every cohort that has examined it. Risk climbs steeply from zero to the low hundreds, then continues rising but flattens in relative terms, because a man with a score of 800 has already accumulated most of the risk that calcium can predict.

A calcium score changes the statin decision most in men whose ten year risk falls between 5 and 20 percent on a standard calculator, which describes the majority of men aged 45 to 65 who are neither obviously healthy nor obviously sick. In that band, the 2018 ACC/AHA guideline states that a score of zero supports withholding a statin, a score of 1 to 99 favours starting one especially if the man is over 55, and a score of 100 or more is a clear indication to treat.

The reclassification effect is large. In the MESA analysis published by Nasir and colleagues in 2015, roughly half of participants who would have been recommended a statin under the pooled cohort equations had a calcium score of zero, and their observed event rate was low enough that treatment offered marginal benefit. Conversely, a substantial minority of participants who did not qualify for a statin on risk factors alone had scores above 100 and event rates that would have justified treatment. The scan corrected the formula in both directions.

Testosterone therapy has been studied against coronary plaque directly, and the findings are more nuanced than either its advocates or its critics usually present. The Cardiovascular Trial within the Testosterone Trials, published by Budoff and colleagues in JAMA in 2017, randomised 170 men over 65 with low testosterone to testosterone gel or placebo for one year and used CT angiography to measure plaque. Non-calcified plaque volume increased more in the testosterone group, by about 41 cubic millimetres versus 14 in placebo, while calcium scores did not differ between groups.

That result deserves careful reading. The trial was small, the men were older than most men considering therapy today, and a one year change in soft plaque volume is a surrogate endpoint whose clinical meaning is uncertain. The much larger TRAVERSE trial, published in 2023, randomised 5,246 men aged 45 to 80 with low testosterone and existing cardiovascular risk to testosterone or placebo for a mean of 22 months and found no increase in major adverse cardiac events. The practical implication is that a man considering testosterone therapy has a good reason to know his calcium score first, not because the score forbids treatment but because it determines how tightly his ApoB, blood pressure and haematocrit should be managed alongside it.

The pie chart is an illustrative weighting rather than a published variance decomposition. What it is meant to convey is that the single largest lever a man has over his future calcium score is the number of ApoB particles his arteries have been exposed to and for how long, which is why lipid lowering started at 45 changes the trajectory more than the same treatment started at 65. Lipoprotein(a), covered in a separate article on this site, is the genetic component that most often explains a high score in a man whose LDL and lifestyle look unremarkable.

A calcium score is most useful for men aged 40 to 75 whose estimated ten year cardiovascular risk falls in the intermediate range of 5 to 20 percent and who are undecided about starting lipid lowering therapy. It is also reasonable for men with a family history of early coronary disease, men with elevated lipoprotein(a), and men considering testosterone therapy who want a baseline. The scan adds little for a man who already has established coronary disease, since he is already in the highest treatment tier, and it adds little for a 30 year old, since calcification takes decades to appear and a zero at 30 means almost nothing.

1. 1Ask a physician for a referral or book directly with an imaging centre, since many US and Australian centres accept self-referral for calcium scoring and price it between $100 and $200 without insurance
2. 2Confirm the centre uses a multidetector CT with ECG gating and reports a standard Agatston score, since some centres offer non-gated chest CT that produces an unreliable estimate
3. 3Avoid caffeine and nicotine for four hours beforehand, because a resting heart rate below about 70 improves image quality and some centres will administer a beta blocker if the rate is higher
4. 4Request the full report rather than a summary, including the per-vessel breakdown, since calcium concentrated in the left main or proximal left anterior descending artery carries more weight than the same total spread across distal vessels
5. 5Run the score through the MESA percentile calculator to see where it falls for a man of the same age and ethnicity, since the percentile often matters more than the raw figure
6. 6Bring the result to a physician alongside a recent lipid panel including ApoB and lipoprotein(a), because the score is a reason to act on those numbers rather than a replacement for them
7. 7If the score is zero, diary a repeat in three to five years, sooner with diabetes, smoking or a strong family history. If the score is above zero, a repeat is generally unnecessary because the treatment decision has been made and progression under statin therapy is expected

A man with a positive calcium score should treat the result as a confirmed diagnosis of coronary atherosclerosis and act on the modifiable drivers immediately, starting with ApoB, blood pressure and glucose. The evidence that this changes outcomes comes from decades of lipid lowering trials, and the calcium score's role is to identify which men those trials apply to. A score of 150 at age 52 is not an emergency, but it is the end of the period in which lifestyle intention without measurement was an acceptable strategy.

One point that surprises many men is that a statin will make the calcium score go up. Statins stabilise plaque partly by promoting calcification, converting soft lipid rich lesions into dense calcified ones that are less likely to rupture. A man whose score rises from 150 to 220 over three years on treatment may have less dangerous arteries than he did at 150, which is why repeat scanning after a positive result is rarely helpful and why the score should be interpreted once, not tracked like a bathroom scale.

A calcium score is worth getting for most men aged 45 to 70 who have not already been classified as very high or very low risk, because it costs about the same as one specialist visit, carries minimal radiation, and reclassifies risk more accurately than any blood test or risk calculator available. The scan is not a substitute for knowing ApoB, lipoprotein(a), blood pressure and glucose, and it does not see the soft plaque that causes events in younger men. It answers one specific question, which is whether the process those numbers describe has already left a footprint.

For a man who has spent years managing a borderline LDL through diet and intention, the score is the closest thing to an audit of whether the strategy worked. A zero says the approach can continue with a recheck in four years. A 200 says the approach has run its course and pharmacological support is now the evidence based path. Either result is more useful than another year of guessing from a lipid panel.

Continue Reading

Related Articles

Hormones

Cholesterol, ApoB, and TRT: What Testosterone Therapy Actually Does to Your Lipid Panel

12 min read

Read Article →

Lab Markers

Lipoprotein(a) in Men Over 40: The Inherited Risk Marker You Only Need To Test Once

12 min read

Read Article →

Lab Markers

hs-CRP in Men Over 40: The Inflammation Marker Most Blood Panels Leave Off

11 min read

Read Article →